Astrazeneca plc recently provided details on the discovery of the potent, direct and selective NLPR3 inflammasome inhibitor AZD-4144 for the treatment of inflammatory diseases; the drug is currently ...
FOLFOX alone or combined to rilotumumab or panitumumab as first-line treatment in patients (pts) with advanced gastroesophageal adenocarcinoma (AGEA): An open-label, randomized phase II trial (PRODIGE ...
Glucokinase activator AZD1656 shows potential benefit for diabetics with moderate to severe COVID-19
Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes a wide range of clinical features, from completely asymptomatic infections to fatal or life-threatening disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback